BioXcel Therapeutics Investor Relations Material

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's primary product candidate, UB-311, utilizes unique artificial intelligence-based technology platforms to identify new indications for existing drugs and to uncover new applications for combinatorial therapeutics.